How Exercise Can Influence Oxidative Stress and Glucose Levels after Pancreatic Resection: A Randomised Controlled Trial

2019 ◽  
Vol 37 (3) ◽  
pp. 205-210
Author(s):  
Anastasios Katsourakis ◽  
Ioannis Vrabas ◽  
Charalambos Dimitriadis ◽  
Stylianos Apostolidis ◽  
Stamatis Aggelopoulos ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Randomised Controlled Trial ◽  
Glycaemic Control ◽  
Pancreatic Resection ◽  
Controlled Trial ◽  
High Morbidity ◽  
Open Label ◽  
Glucose Levels ◽  
Randomised Controlled ◽  
Positive Effect

Background: One of the most challenging operations is the resection of the pancreas, which is associated with high morbidity. Metabolic control during the perioperative period remains an issue that is sometimes difficult to manage. Objectives: Exercise has a positive effect on glycaemic control. The objective of this trial was determining whether exercise has any benefit for oxidative stress and glucose levels. Method: The study was an open-label, randomised clinical trial. It has been registered in the International Standard Randomised Controlled Trial registry. The patients were selected according to the Consolidated Standard of Reporting Trials criteria. Results: In total, 56 patients were assessed for eligibility. There was no statistical difference between the 2 groups (the exercise and the control one) regarding the disease characteristics, morbidity or influence of exercise on oxidative stress; however, the control of glucose was superior in the exercise group. Conclusions: Exercise has a positive effect on glycaemic control in patients after pancreatic resection.

scholarly journals Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: study protocol for a pilot randomised controlled trial

BJPsych Open ◽  
2015 ◽  
Vol 1 (1) ◽  
pp. 67-73 ◽  
Author(s):  
Karla Mayfield ◽  
Dan Siskind ◽  
Karl Winckel ◽  
Samantha Hollingworth ◽  
Steve Kisely ◽  
...  
Keyword(s):  
Weight Loss ◽  
Randomised Controlled Trial ◽  
Glycaemic Control ◽  
Controlled Trial ◽  
Metabolic Disturbances ◽  
Open Label ◽  
Treatment As Usual ◽  
Pilot Randomised Controlled Trial ◽  
Obesity And Diabetes ◽  
Randomised Controlled

BackgroundClozapine causes significant metabolic disturbances including obesity and type 2 diabetes. Recent evidence that reduced glucagon-like-peptide-1 (GLP-1) may contribute to aetiology of clozapine-associated metabolic dysregulation suggests a potential therapeutic role for GLP-1 agonists.MethodThis open-label, pilot randomised controlled trial evaluates the effect of exenatide in clozapine-treated obese adults who have schizophrenia, with or without poorly controlled diabetes. Sixty out-patients will be randomised to once weekly extended release exenatide or treatment as usual for 24 weeks.AimsTo evaluate the feasibility of larger studies regarding methodology, acceptability, tolerability and estimate efficacy for glycaemic control or weight loss. Secondary outcomes are psychosis severity and metabolic parameters.ConclusionsThis is the first trial investigating GLP-1 agonists for glycaemic control and weight loss in clozapine-treated patients with either diabetes or obesity. Clozapine-associated obesity and diabetes with exenatide (CODEX) will provide proof-of-concept empirical evidence addressing whether this novel treatment is practical and worthy of further investigation.

Sign in / Sign up

Export Citation Format

Share Document